Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Expression of activated type I receptor tyrosine kinases in early breast cancer.

Spears M, Pederson HC, Lyttle N, Gray C, Quintayo MA, Brogan L, J Thomas JS, Kerr GR, Jack WJ, Kunkler IH, Cameron DA, Chetty U, Bartlett JM.

Breast Cancer Res Treat. 2012 Jul;134(2):701-8. doi: 10.1007/s10549-012-2076-7. Epub 2012 May 5.

PMID:
22562124
2.

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.

Breast Cancer Res. 2009;11(1):R11. doi: 10.1186/bcr2230. Epub 2009 Feb 24.

3.

HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.

Bae SY, La Choi Y, Kim S, Kim M, Kim J, Jung SP, Choi MY, Lee SK, Kil WH, Lee JE, Nam SJ.

Breast Cancer Res Treat. 2013 Jun;139(3):741-50. doi: 10.1007/s10549-013-2570-6. Epub 2013 May 31.

PMID:
23722313
4.

Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.

Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI.

Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S99-S111. Review.

5.

HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.

Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M, Bendahl PO.

Breast Cancer Res Treat. 2008 May;109(2):351-7. Epub 2007 Jul 18.

PMID:
17636399
6.
7.

Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy.

Larsen MS, Bjerre K, Lykkesfeldt AE, Giobbie-Hurder A, Laenkholm AV, Henriksen KL, Ejlertsen B, Rasmussen BB.

Breast. 2012 Oct;21(5):662-8. doi: 10.1016/j.breast.2012.07.005. Epub 2012 Jul 31.

8.

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.

Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R, Baum M.

Ann Oncol. 2006 May;17(5):818-26. Epub 2006 Feb 23.

9.

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.

Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ.

J Clin Oncol. 2008 Nov 1;26(31):5027-35. doi: 10.1200/JCO.2007.14.6597. Epub 2008 Sep 2.

10.

HER2 overexpression and activation, and tamoxifen efficacy in receptor-positive early breast cancer.

Singer CF, Gschwantler-Kaulich D, Fink-Retter A, Pfeiler G, Walter I, Hudelist G, Helmy S, Spiess AC, Lamm W, Kubista E.

J Cancer Res Clin Oncol. 2009 Jun;135(6):807-13. doi: 10.1007/s00432-008-0516-x. Epub 2008 Nov 26.

PMID:
19034514
11.

Estrogen receptor alpha phosphorylated at tyrosine 537 is associated with poor clinical outcome in breast cancer patients treated with tamoxifen.

Skliris GP, Nugent Z, Watson PH, Murphy LC.

Horm Cancer. 2010 Aug;1(4):215-21. doi: 10.1007/s12672-010-0049-z.

PMID:
21761367
12.

Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.

Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, Elmberger G, Skoog L, Bergh J.

Med Oncol. 2009 Dec;26(4):480-90. doi: 10.1007/s12032-008-9157-9. Epub 2009 Jan 7.

PMID:
19130322
13.

In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer.

Spears M, Taylor KJ, Munro AF, Cunningham CA, Mallon EA, Twelves CJ, Cameron DA, Thomas J, Bartlett JM.

Breast Cancer Res Treat. 2012 Apr;132(2):463-70. doi: 10.1007/s10549-011-1606-z. Epub 2011 Jun 3.

PMID:
21638049
14.

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M.

J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28.

15.

Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer.

Bjerre C, Knoop A, Bjerre K, Larsen MS, Henriksen KL, Lyng MB, Ditzel HJ, Rasmussen BB, Brünner N, Ejlertsen B, Laenkholm AV.

Acta Oncol. 2013 Jan;52(1):82-90. doi: 10.3109/0284186X.2012.734922. Epub 2012 Dec 4.

PMID:
23205744
16.

The p160 ER co-regulators predict outcome in ER negative breast cancer.

Spears M, Oesterreich S, Migliaccio I, Guiterrez C, Hilsenbeck S, Quintayo MA, Pedraza J, Munro AF, Thomas JS, Kerr GR, Jack WJ, Kunkler IH, Cameron DA, Chetty U, Bartlett JM.

Breast Cancer Res Treat. 2012 Jan;131(2):463-72. doi: 10.1007/s10549-011-1426-1. Epub 2011 Mar 9.

PMID:
21390497
17.

Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer.

Campbell EJ, McDuff E, Tatarov O, Tovey S, Brunton V, Cooke TG, Edwards J.

Br J Cancer. 2008 Dec 2;99(11):1769-74. doi: 10.1038/sj.bjc.6604768. Epub 2008 Nov 18.

18.

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.

Rydén L, Jirström K, Haglund M, Stål O, Fernö M.

Breast Cancer Res Treat. 2010 Apr;120(2):491-8. doi: 10.1007/s10549-010-0758-6. Epub 2010 Feb 5.

PMID:
20135347
19.

HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.

Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM.

Clin Cancer Res. 2004 Sep 1;10(17):5670-6.

20.

A phosphorylation code for oestrogen receptor-alpha predicts clinical outcome to endocrine therapy in breast cancer.

Skliris GP, Nugent ZJ, Rowan BG, Penner CR, Watson PH, Murphy LC.

Endocr Relat Cancer. 2010 Jun 3;17(3):589-97. doi: 10.1677/ERC-10-0030. Print 2010 Sep.

Items per page

Supplemental Content

Write to the Help Desk